Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Tyme Technologies Inc    TYME

TYME TECHNOLOGIES INC (TYME)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyConsensus 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/15/2018 06/18/2018 06/19/2018 06/20/2018 06/21/2018 Date
3.81(c) 3.45(c) 3.72(c) 3.55(c) 3.525 Last
408 816 304 173 200 472 182 449 19 177 Volume
+8.24% -9.45% +7.83% -4.57% -0.70% Change
More quotes
Financials (USD)
Sales 2017 -
EBIT 2017 -22,0 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales2017 0
Capi. / Sales2018 -
Capitalization 371 M
More Financials
Company
Tyme Technologies, Inc. operates as a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications.Its clinical program, SM-88 is a novel combination therapy based on dysfunctional metyrosine... 
More about the company
Latest news on TYME TECHNOLOGIES INC
06/13TYME TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
06/12Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Stud..
GL
06/12TYME TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
05/30Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors
GL
05/29TYME TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Other Event..
AQ
05/17TYME TECHNOLOGIES : Announces Five Clinical Abstracts at the 2018 ASCO Annual Me..
AQ
04/12TYME TECHNOLOGIES : Provides Clinical and Corporate Update for Fiscal Year End 2..
AQ
04/10TYME TECHNOLOGIES : and JAF Announce Sarcoma Treatment Collaboration
AQ
04/09TYME TECHNOLOGIES, INC. : Results of Operations and Financial Condition, Financi..
AQ
04/09Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
GL
More news
Sector news : Bio Therapeutic Drugs
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09:30aTyme Technologies Inc $TYME Given Average Recommendation of “Hold” by Brokera.. 
06/17Tyme Technologies $TYME Earns “Buy” Rating from Canaccord Genuity  
06/17Tyme Technologies $TYME Rating Reiterated by Canaccord Genuity  
06/15Analysts Are Bullish on These Healthcare Stocks: TYME, BMRN $TYME  
06/14Analysts Expect Tyme Technologies Inc $TYME to Announce -$0.08 EPS  
More tweets
Qtime:14
News from SeekingAlpha
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
06/12Tyme Technologies' SM-88 shows anti-tumor effect across range of cancers; sha.. 
06/12HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/12/2018) 
05/24HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/24/2018) 
03/14PREMARKET GAINERS AS OF 9 : 05 am (03/14/2018) 
Chart TYME TECHNOLOGIES INC
Duration : Period :
Tyme Technologies Inc Technical Analysis Chart | TYME | US90238J1034 | 4-Traders
Technical analysis trends TYME TECHNOLOGIES INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 8,83 $
Spread / Average Target 149%
Managers
NameTitle
Steve Hoffman Chief Executive & Science Officer, Director
Ben Taylor President & Chief Financial Officer
Michael Demurjian Chief Operating Officer, Director & Executive VP
Guiseppe Del Priore Chief Medical Officer
Jonathan M. Eckard Chief Scientific Affairs Officer
Sector and Competitors
1st jan.Capitalization (M$)
TYME TECHNOLOGIES INC-44.36%371
GILEAD SCIENCES-0.98%92 241
VERTEX PHARMACEUTICALS3.10%39 371
REGENERON PHARMACEUTICALS-13.00%34 653
SAREPTA THERAPEUTICS INC176.22%9 432
NEUROCRINE BIOSCIENCES, INC.32.39%9 234